Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 48

    1.

    Dichlorodiphenyltrichloroethane and risk of hepatocellular carcinoma.

    Persson EC, Graubard BI, Evans AA, London WT, Weber JP, Leblanc A, Chen G, Lin W, McGlynn KA.

    Int J Cancer. 2012 Jan 30. doi: 10.1002/ijc.27459. [Epub ahead of print]

    PMID:
    22290210
    [PubMed - as supplied by publisher]
    2.

    A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome.

    Guo Z, Wu C, Wang X, Wang C, Zhang R, Shan B.

    Int J Cancer. 2011 Nov 18. doi: 10.1002/ijc.27352. [Epub ahead of print]

    PMID:
    22095217
    [PubMed - as supplied by publisher]
    3.

    Hepatoblastoma in the nordic countries.

    de Fine Licht S, Schmidt LS, Rod NH, Schmiegelow K, Lähteenmäki PM, Kogner P, Träger C, Stokland T, Schüz J.

    Int J Cancer. 2011 Nov 18. doi: 10.1002/ijc.27351. [Epub ahead of print]

    PMID:
    22095187
    [PubMed - as supplied by publisher]
    4.

    Type 2 diabetes and hepatocellular carcinoma: A case-control study in patients with chronic hepatitis B.

    Li Q, Li WW, Yang X, Fan WB, Yu JH, Xie SS, Liu L, Ma LX, Chen SJ, Kato N.

    Int J Cancer. 2011 Nov 2. doi: 10.1002/ijc.27337. [Epub ahead of print]

    PMID:
    22052244
    [PubMed - as supplied by publisher]
    5.

    Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma.

    Wang XQ, Zhang W, Lui EL, Zhu Y, Lu P, Yu X, Sun J, Yang S, Poon RT, Fan ST.

    Int J Cancer. 2012 Aug 1;131(3):E163-72. doi: 10.1002/ijc.27336. Epub 2011 Dec 14.

    PMID:
    22052196
    [PubMed - in process]
    6.

    Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma.

    Prakobwong S, Charoensuk L, Hiraku Y, Pinlaor P, Pairojkul C, Mairiang E, Sithithaworn P, Yongvanit P, Khuntikeo N, Pinlaor S.

    Int J Cancer. 2011 Sep 20. doi: 10.1002/ijc.26443. [Epub ahead of print]

    PMID:
    21935919
    [PubMed - as supplied by publisher]
    7.

    Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials.

    Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS.

    Int J Cancer. 2011 Sep 1;129(5):1254-64. doi: 10.1002/ijc.25767. Epub 2011 Jan 6.

    PMID:
    21710498
    [PubMed - indexed for MEDLINE]
    8.

    Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage.

    Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, Kanai Y.

    Int J Cancer. 2011 Sep 1;129(5):1170-9. doi: 10.1002/ijc.26061. Epub 2011 May 9.

    PMID:
    21400512
    [PubMed - indexed for MEDLINE]
    9.

    Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.

    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.

    Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.

    PMID:
    21858812
    [PubMed - in process]
    10.

    Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement.

    Ban G, Jeong JS, Kim A, Kim SJ, Han SY, Kim IH, Lee SW.

    Int J Cancer. 2011 Aug 15;129(4):1018-29. doi: 10.1002/ijc.25988. Epub 2011 Apr 13.

    PMID:
    21328343
    [PubMed - indexed for MEDLINE]
    11.

    Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.

    Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M.

    Int J Cancer. 2012 Jun 15;130(12):2912-21. doi: 10.1002/ijc.26330. Epub 2011 Sep 12.

    PMID:
    21796631
    [PubMed - in process]
    12.

    PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma.

    Dituri F, Mazzocca A, Lupo L, Edling CE, Azzariti A, Antonaci S, Falasca M, Giannelli G.

    Int J Cancer. 2012 Jun 1;130(11):2505-13. doi: 10.1002/ijc.26319. Epub 2012 Jan 24.

    PMID:
    21796621
    [PubMed - indexed for MEDLINE]
    13.

    Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis.

    Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH.

    Int J Cancer. 2012 Jun 1;130(11):2685-92. doi: 10.1002/ijc.26301. Epub 2011 Sep 14.

    PMID:
    21780114
    [PubMed - indexed for MEDLINE]
    14.

    3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells.

    Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A, Yokosuka O.

    Int J Cancer. 2012 Jun 1;130(11):2557-67. doi: 10.1002/ijc.26264. Epub 2011 Aug 20.

    PMID:
    21717453
    [PubMed - indexed for MEDLINE]
    15.

    αL β2 integrin is indispensable for CD8+ T-cell recruitment in experimental pancreatic and hepatocellular cancer.

    Takeichi T, Mocevicius P, Deduchovas O, Salnikova O, Castro-Santa E, Büchler MW, Schmidt J, Ryschich E.

    Int J Cancer. 2012 May 1;130(9):2067-76. doi: 10.1002/ijc.26223. Epub 2011 Aug 16.

    PMID:
    21647874
    [PubMed - indexed for MEDLINE]
    16.

    Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study.

    Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH.

    Int J Cancer. 2011 Jun 1;128(11):2717-25. doi: 10.1002/ijc.25596. Epub 2010 Oct 13.

    PMID:
    20715167
    [PubMed - indexed for MEDLINE]
    17.

    Aryl hydrocarbon receptor nuclear translocator is associated with tumor growth and progression of hepatocellular carcinoma.

    Liang Y, Li WW, Yang BW, Tao ZH, Sun HC, Wang L, Xia JL, Qin LX, Tang ZY, Fan J, Wu WZ.

    Int J Cancer. 2012 Apr 15;130(8):1745-54. doi: 10.1002/ijc.26166. Epub 2011 Aug 16.

    PMID:
    21544813
    [PubMed - indexed for MEDLINE]
    18.

    Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies.

    Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, Li G, Wang L.

    Int J Cancer. 2012 Apr 1;130(7):1639-48. doi: 10.1002/ijc.26165. Epub 2011 Jul 28.

    PMID:
    21544812
    [PubMed - in process]
    19.

    The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C.

    Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, Krämer B, Körner C, Odenthal M, Schulze F, Grünhage F, Nattermann J, Sauerbruch T, Spengler U.

    Int J Cancer. 2012 Mar 15;130(6):1470-5. doi: 10.1002/ijc.26143. Epub 2011 Jun 18.

    PMID:
    21500195
    [PubMed - indexed for MEDLINE]
    20.

    Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma.

    Ammerpohl O, Pratschke J, Schafmayer C, Haake A, Faber W, von Kampen O, Brosch M, Sipos B, von Schönfels W, Balschun K, Röcken C, Arlt A, Schniewind B, Grauholm J, Kalthoff H, Neuhaus P, Stickel F, Schreiber S, Becker T, Siebert R, Hampe J.

    Int J Cancer. 2012 Mar 15;130(6):1319-28. doi: 10.1002/ijc.26136. Epub 2011 Jul 21.

    PMID:
    21500188
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk